Rinki Kapoor

Rinki Kapoor

Auto-generated profile, based on publicly available information

Rinki Kapoor

Department of Bioengineering, Stanford University, Stanford, CA 94305, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
RKRinki Kapoor
Rinki Kapoor
MWMayken W. Wadman
Mayken W. Wadman
MDMichelle T. Dohm
Michelle T. Dohm
ACAnn M. Czyzewski
Ann M. Czyzewski
ASAlfred M. Spormann
Alfred M. Spormann
ABAnnelise E. Barron
Annelise E. Barron
The resistance of biofilms to conventional antibiotics complicates the treatment of chronic cystic fibrosis (CF). We investigated the effects of peptoids, peptides, and conventional antibiotics on the biomass and cell viability within Pseudomonas aeruginosa biofilms. At their MICs, peptoids 1 and 1-C13 4mer caused maximum reductions in biomass and cell viability, respectively. These results suggest that peptoids of this class could be worth exploring for the treatment of pulmonary infections occurring in CF patients.

1 June 2011 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
RKRinki Kapoor
Rinki Kapoor
PEPatrick R. Eimerman
Patrick R. Eimerman
JHJonathan W. Hardy
Jonathan W. Hardy
JCJeffrey D Cirillo
Jeffrey D Cirillo
CCChristopher Contag
Christopher Contag
ABAnnelise E. Barron
Annelise E. Barron
Tuberculosis is a leading cause of death worldwide. Resistance of Mycobacterium to antibiotics can make treatments less effective in some cases. We tested selected oligopeptoids—previously reported as mimics of natural host defense peptides—for activity against Mycobacterium tuberculosis and assessed their cytotoxicity. A tetrameric, alkylated, cationic peptoid (1-C13 4mer ) was most potent against M. tuberculosis and least cytotoxic, whereas an unalkylated analogue, peptoid 1 4mer , was inactive. Peptoid 1-C13 4mer thus merits further study as a potential antituberculosis drug.

1 August 2011 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
MDMichelle T. Dohm
Michelle T. Dohm
RKRinki Kapoor
Rinki Kapoor
ABAnnelise E. Barron
Annelise E. Barron
Peptoids are a developing class of peptide-like oligomers originally invented for drug discovery in the early 1990s. While peptides hold great promise for therapeutic applications, current development of peptide-based pharmaceuticals is hindered by their potential for misfolding and aggregation, and particularly, for rapid in vivo degradation post-administration. Researchers have investigated alternative peptide-like constructs that may be able to circumvent such complications. Peptoids comprise a peptide-based backbone and Nsubstituted glycines for side chain residues, resulting in complete protease-resistance. Synthesis of peptoid sequences up to 50 units in length allows for controlled sequence composition and incorporation of diverse side chain chemistries. Though the landscape of peptoid structure is not clearly defined, secondary, tertiary, loop, turn, and random structures have been identified. As protease-resistant isomers of peptides, peptoids are being developed as versatile molecular tools in biochemistry and biophysics, and are becoming attractive candidates for therapeutic and diagnostic applications. Peptoids have thus far demonstrated bioactivity as protein mimics and as replacements for small molecule drugs. In this review, we discuss the most recent advances in peptoid research on the therapeutic front in the last few years, including in vitro and in vivo studies in the fields of lung surfactant therapy, antimicrobial agents, diagnostics, and cancer. We particularly focus on the biophysical activity of lipid-associated peptoids and their potential therapeutic applications.

1 January 2012
Verified
Book Chapter
Closed access
MWM. Wetzer
M. Wetzer
RKR. Kapoor
R. Kapoor
WHW. Huang
W. Huang
ABA.E. Barron
A.E. Barron

1 January 2010 in Biophysical Journal
Verified
Journal Article
Open access
PDF file
RKRinki Kapoor
Rinki Kapoor